ID   MOLM-13-RES
AC   CVCL_D779
DR   Cosmic; 1741689
DR   Cosmic; 2842301
DR   Wikidata; Q54906321
RX   PubMed=22354205;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:90237; Tandutinib (MLN518; CT53518).
CC   Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   NCIt; C3247; Myelodysplastic syndrome
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2119 ! MOLM-13
SX   Male
AG   20Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=22354205; DOI=10.1038/leu.2012.52;
RA   Moore A.S., Faisal A., Gonzalez de Castro D., Bavetsias V., Sun C.,
RA   Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D.,
RA   Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J.,
RA   Raynaud F.I., Eccles S.A., Linardopoulos S.;
RT   "Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia
RT   resulting in secondary D835Y mutation: a model for emerging clinical
RT   resistance patterns.";
RL   Leukemia 26:1462-1470(2012).
//